With the increasing use of fluorescence-based assays in high-throughput screening (HTS), the possibility of interference by fluorescent compounds needs to be considered. To investigate compound interference, a well-defined sample set of biologically active compounds, LOPAC™, was evaluated using 4 fluorescein-based fluorescence polarization (FP) assays. Two kinase assays, a protease assay, and a phosphatase assay were studied. Fluorescent compound interference and light scattering were observed in both mixture-and single-compound testing under certain circumstances. In the kinase assays, which used low levels (1-3 nM) of fluorophore, an increase in total fluorescence, an abnormal decrease in mP readings, and negative inhibition values were attributed to compound fluorescence. Light scattering was observed by an increase in total fluorescence and minimal reduction in mP, leading to false positives. The protease and phosphatase assays, which used a higher concentration of fluorophore (20-1200 nM) than the kinase assays, showed minimal interference from fluorescent compounds, demonstrating that an increase in the concentration of the fluorophore minimized potential fluorescent compound interference. The data also suggests that mixtures containing fluorescent compounds can result in either false negatives that can mask a potential "hit" or false positives, depending on the assay format. Cy™ dyes (e.g., Cy3B™ and Cy5™) excite and emit further into the red region than fluorescein and, when used in place of fluorescein in kinase 1, eliminate fluorescence interference and light scattering by LOPAC™ compounds. This work demonstrates that fluorescent compound and light scattering interferences can be overcome by increasing the fluorophore concentration in an assay or by using longer wavelength dyes. (Journal of Biomolecular Screening 2003:176-184) 
INTRODUCTION
F LUORESCENCE-BASED ASSAYS have become increasingly popular as an assay format for high-throughput screening (HTS). [1] [2] [3] There are a number of advantages in developing fluorescencebased assays. They are nonradioactive, in many cases homogeneous, and most often sensitive enough to be miniaturized to very low volumes. Fluorescence-based technologies that are routinely being used in HTS include fluorescence intensity (FI), timeresolved fluorescence (TRF), and fluorescence polarization (FP).
The FP method has become especially popular because it requires only 1 labeled assay component and is ratiometric. 4, 5 This article focuses on FP and the interference observed when libraries containing fluorescent and/or insoluble compounds are screened in FP assays.
One concern in running FP assays is compound interference. This interference can either be due to fluorescence compounds or insoluble compounds in the libraries. The 2 main factors that contribute to compound interference are the concentration of the fluorophore and the emission wavelength of the fluorophore. The most commonly used fluorophore to date is fluorescein. When used at low concentrations, fluorescence contributions from library compounds will have a more dramatic impact on the assay because the detection readout is a measure of the sum of all fluorescent species in the assay. As the fluorophore concentration increases in the assay, the contributions from other fluorescent compounds reduce. Use of fluorescein with an emission at 530 nm increases the likelihood of generating false positives or negatives, depending on the assay format because many fluorescent compounds emit in this region. Red-shifted fluorophores, such as BODIPY-TMR and Cy™ dyes, are viable options for reducing fluorescence interference because fewer compounds emit at these longer wavelengths. 6, 7 Furthermore, longer wavelength fluorophores may help reduce light scattering caused by compound insolubility because the intensity of scattered light decreases with increasing wavelength. This is based on the concept of Rayleigh scattering, where the intensity is related to wavelength (an inverse fourth-power effect), the dimensions of the scattering particles, and their polarizability. 6, 8 In this paper, 4 FP assays that use fluorescein were examined to gain a better understanding of fluorescence compound interference and light scattering interference: 2 kinases, a protease, and a phosphatase assay. In addition, the kinase 1 assay was tested using Cy3B™ and Cy5™ fluorophores. The assays were tested using a well-defined sample set of biologically active compounds termed LOPAC™. Comparisons between the 4 assays indicated significant fluorescent compound interference when low concentrations of fluorophore were present in the assay. It was also found that light scattering interferences diminished with use of red-shifted fluorophores.
MATERIALS AND METHODS

Materials
Black 384-well plates were purchased from Apogent Discoveries (Hudson, NH). 2-[4-(2-Hydroxyethyl)-1-piperazine] ethanesulfonic acid (HEPES) in 1 M solution, ethylenediaminetetraacetic acid (EDTA) in 0.5 M solution, and Tris•HCl in 1 M solution were purchased from GIBCO BRL (Frederick, MD). Magnesium chloride (MgCl 2 ), dithiotreitol (DTT), sodium orthovanadate (Na 3 VO 4 ), adenosine 5′-triphosphate (ATP), and staurosporine were purchased from Sigma Chemical Company (St. Louis, MO). Zinc chloride (ZnCl 2 ) and sodium acetate (NaOAc) were purchased from Fisher Scientific (Fair Lawn, NJ). Peptide substrates and Fl-PO 4 -peptides in kinase assays 1 and 2 were designed inhouse and prepared by SynPep Corporation (Dublin, CA). Cy5™-PO 4 -peptide and Cy3B™-PO 4 -peptide used in kinase assay 1 were purchased from Amersham Biosciences (Piscataway, NJ). Protease assay peptide substrate was purchased from AnaSpec (San Jose, CA), and generic fluorescein-diphosphate (FDP) and biotinylated fluorescein for the phosphatase assay were purchased from Molecular Probes (Eugene, OR). Antibodies for kinase 1 and kinase 2 were purchased from Upstate Biotechnology (Lake Placid, NY) and Medical and Biological Labs (Watertown, MA), respectively. The complete protease inhibitor cocktail tablets containing chymotrypsin, thermolysin, papain, pronase, pancreatic extract, and trypsin were purchased from Boehringer Mannheim (Indianapolis, IN). Avidin was purchased from Pierce (Rockford, IL). KB8301 was purchased from Pharmingen (San Diego, CA). Suramin hexasodium and N-ethylmaleimide (NEM) were pur-chased from Calbiochem (San Diego, CA). The collection of 640 LOPAC™ compounds was purchased as a set from Sigma-RBI (Natick, MA), and mixtures of 8 were prepared in-house at a final concentration of 100 µg/mL in 100% DMSO. Mixtures of interest were further deconvoluted to identify individual compounds.
All fluorescence polarization readings were performed on the Analyst from Molecular Devices (Sunnyvale, CA). For fluorescein-based assays, the Analyst was set for an excitation wavelength of 485 nm with a bandwidth of 20 nm and emission at 530 nm with a bandwidth of 25 nm. The dichroic filter was 505 nm, and the read time ranged from 1 to 3 s per well. For Cy3B™, the Analyst was set to excite at 530 nm with a bandwidth of 25 nm and emit at 580 nm with a bandwidth of 10 nm, and the dichroic filter was 560 nm. For Cy5™, the Analyst was set to excite at 640 nm with a bandwidth of 20 nm and emit at 682 nm with a bandwidth of 22 nm, and the dichroic filter was 650 nm. Note that sensitivity adjustments were optimized for each individual assay. The emission intensity measurement from the S plane, P plane, and mP values was obtained directly from the Analyst output software without correction for G factor. Delta mP (∆mP) was used to determine the window of the assay using the following equation:
where mP pos was considered the complete reaction containing no inhibitor (positive control), and mP neg was considered complete inhibition using a known inhibitor for each assay (negative control). Total fluorescence (TF) was determined using the following emission intensity measurements:
Fluorescence intensity measurements were obtained using an AVIV spectrofluorometer (Lakewood, NJ). The excitation wavelength was 485 nm with a bandwidth of 3 nm, and the emission wavelength was 530 nm with a bandwidth of 3 nm.
Specific positive and negative controls were run for each assay. Actives were defined as samples with greater than or equal to 50% inhibition. If a mixture well was active, the 8 compounds were deconvoluted to determine which individual compound inhibited the enzyme 50% or more.
Assay conditions
Assays were performed according to Figure 1 . The LOPAC™ compounds were diluted in water/DMSO as appropriate to have a final assay concentration of 2 µg/mL in 2% DMSO. The assay additions for all 4 assays were 13 µL of compound, 10 µL of enzyme, and 10 µL of substrate in a 384-well black plate. After incubation, the reactions were stopped and the assay plates read on the Analyst. TF, mP values, and percentage inhibition were used for interpretation of the data. The specific assay conditions are summarized
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in Table 1 , where all concentrations denoted were final concentrations in the reactions.
The LOPAC™ mixtures were tested for inherent compound fluorescence by running the compounds in assay buffer without fluorophore. The wells contained 13 µL of compound and 20 µL of assay buffer. The plates were read on the Analyst without an incubation time.
The experiments for kinase 1 using the Cy™ fluorophores in place of Fl-PO 4 -peptide were run using the same peptide sequence with only the fluorophore being changed. The assay used the same final concentration for all reagents, as denoted in Table 1 , except for the Cy™ fluorophore concentration. Cy5™-PO 4 -peptide was run at 1 nM fluorophore, and Cy3B™-PO 4 -peptide was run at 5 nM fluorophore. Fluorophore concentrations were 10 times above the background value (buffer only).
RESULTS AND DISCUSSION
Identification of fluorescent compounds in the LOPAC™ sample set
The LOPAC™ sample set of 80 mixtures was placed in each of the 4 assay buffers containing no fluorophore and read on the Analyst to identify intrinsically fluorescent compounds. The mixture wells whose TF were greater than or equal to the TF of 1 nM fluorescein, used as the control, were deconvoluted and analyzed individually to identify the compound(s) in the mixture that were intrinsically fluorescent. The fluorescein concentration at 1 nM was chosen as the comparison because the Analyst has a detection limit of 100 pM fluorescein. 4 The result for the 80 mixtures tested in the kinase 1 assay buffer is shown in Figure 2 . Similar results were found for the mixtures when tested in the other 3 assay buffers (data not shown). Figure 2 consists of TF values for each mixture well, along with standard Table 2 . Seven of the 8 mixtures contained 1 compound exhibiting a TF greater than or nearly equal to that obtained using 1 nM fluorescein, suggesting that these compounds were intrinsically fluorescent. Mix 37 did not deconvolute into an individual fluorescent compound with a TF value near that associated with 1 nM fluorescein; rather, it contained 2 compounds that showed slightly elevated TF. The increase in TF in mix 37 was presumably due to an additive affect of the 2 compounds each containing some fluorescent characteristics. Table 2 shows the TF and mP values found for the deconvoluted fluorescent compounds. High TF and low mP values are associated with fluorescent compounds; however, 1 compound identified, sepiapterin, had a high TF and high mP value. Not only does sepiapterin contain fluorescence properties, but it is also not completely soluble (visual inspection), thus causing light scattering. Light scattering results not only in high TF but also high mP values because the scattered light is usually 100% polarized. 9 The 7 compounds that displayed high TF were further evaluated for their fluorescent properties using an AVIV spectrofluorometer as illustrated in Figures 3A and 3B . The compounds' relative fluorescence unit (RFU) values were determined at various compound concentrations by exciting at 485 nm and reading the emission at 530 nm ( Figure 3B ). The compounds' RFU values were compared to those generated for a standard fluorescein curve displayed in Figure 3A . Both fluorescein and all 7 compounds showed good correlation between increasing fluorescence intensity and increasing concentration of the compound. Because the compounds were tested at 2 µg/mL in the 4 assays, Figure 3B shows that all 7 compounds contained some fluorescence characteristics at this concentration. Comparing those RFU values to the standard fluorescein curve in Figure 3A , one can see that the compounds exhibited similar fluorescence as fluorescein at low nM concentrations. Therefore, if the fluorophore in the assay is at low nM concentrations, as is the case for the 2 kinase assays, one would expect these compounds to contribute their fluorescence in the assay and thereby interfere with the readout. The structures of the 7 compounds that exhibited fluorescence are displayed in Figure 4 . All of these compounds have some intrinsic fluorescent properties. Compounds with extended π conjugation and compounds that display amino groups on or near these fused ring systems allowing n to π* transitions have the appropriate characteristics to be intrinsically fluorescent. 9, 10 Dipyridamole was identified from mix 5 as a yellow solution that shows strong blue-green fluorescence. 11 Agroclavine, ergocristine, and ergometrine maleate were identified as the fluorescent compounds from mix 31, 35, and 36, respectively. 12 These 3 compounds contain the same 4 fused-ring core structure. Sepiapterin, a pterin derivative, was identified as the compound from mix 59. Besides being fluorescent, this compound was partially insoluble, causing light scattering. 11, 13, 14 The compound identified in mix 65 was 5,7dihydroxytryptamine creatinine sulfate, which belongs to the tryptophan family, and is known to be a natural fluorophore. 9, 15 Finally, quinacrine dihydrochloride was identified as the fluorescent compound from mix 79. This compound exhibits vivid fluorescence due to the 3 fused benzene rings having extended π conjugation. 9, 16, 17 
Results for testing of the LOPAC™ sample set in the 4 FP assays
Inhibition of kinase assay 1, a ser/thr kinase, was measured using a competitive FP assay with a product-specific antiphosphoserine antibody as shown in Figure 1A . 18 The assay was run with 1 nM Fl-PO 4 -peptide. The results are displayed in Table 3 for the compounds identified as interfering with the assay and compounds identified as inhibitors of the assay. All 7 compounds identified as fluorescent were affecting the performance of the assay. Six of the 7 compounds exhibited high TF values compared to the DMSO/water control and negative percentage inhibition values. In these cases, the strong fluorescence from the compounds made a significant contribution to the polarization measurement, resulting in decreased mP readings and negative inhibition values for the signal decrease assay. In other words, when compound fluorescence is of the same order of magnitude as the fluorophore signal, the measurement is compromised. Sepiapterin was the 1 fluorescent compound that gave a high TF reading but also inhibited the assay by greater than 50%. This inhibition was due to an increased mP value caused by compound insolubility rather than true inhibition. A total of 3 compounds were identified as inhibitors of the assay: H-9 dihydrochloride, a known protein kinase inhibitor, 19, 20 and 2 dopamine analogs. Kinase assay 2, a ser/thr kinase, was formatted the same as kinase assay 1. The assay was run with 3 nM Fl-PO 4 -peptide, a slightly higher concentration than that used in kinase assay 1. The results are displayed in Table 4 , where 6 of the 7 compounds identified as fluorescent were affecting the performance of the assay. 5,7-Dihydroxytryptamine creatinine sulfate did not interfere with the signal generated. One explanation is that the fluorophore concentration was increased to 3 nM from 1 nM in kinase 1. This 3fold increase in fluorophore was enough to minimize the fluorescent compound's contribution to the signal. Furthermore, 5,7dihydroxytryptamine creatinine sulfate was the least fluorescent of the 7 compounds when tested in mixtures in kinase 1, attesting to its negligible affect in kinase 2. Of the 6 compounds that exhibited high TF values compared to the control, DMSO/water, 5 had negative percentage inhibition values. Thus, they interfered with the readout as observed with kinase 1. Sepiapterin was the 1 fluorescent compound that gave a high TF reading but also inhibited the assay by greater than 50%. This inhibition, as discussed above, was due to compound insolubility rather than true inhibition, leading to a false-positive hit. A total of 2 compounds were identified as inhibitors of the assay: 4,5-dianilinophthalimide, a known protein kinase inhibitor, 21, 22 and 2-phenylaminoadenosine, which has shown in 2 different assay formats, FP and Flashplate (data not shown), to cause inhibition of kinase 2 activity. The 2 dopamine analogs identified in kinase 1 as active were also weak inhibitors of kinase 2, showing 31% and 30% inhibition, respectively (data not shown).
The protease assay format is summarized in Figure 1B , where one measured directly the enzymatic cleavage of the biotinylated fluoresceinated peptide with the addition of avidin. This assay was run at 20 nM fluorophore, and it was found that none of the 7 fluorescent compounds were interfering with the assay readout, no abnormally high TF values compared to the control, DMSO/water. Therefore, the mP values generated from the Analyst software and percentage inhibition values calculated were within the expected values based on the positive and negative controls. The 7 fluorescent compounds did not cause substantially high TF values in this assay because the fluorescent peptide was run at a high enough concentration (20 nM) that additional fluorescence associated with compounds was not significant enough to affect the assay. In this assay, there were no active compounds identified from screening the LOPAC™ sample set. Last, the phosphatase assay was formatted as illustrated in Figure 1C . In this assay, one measures the generation of fluorescein through the dephosphorylation of FDP, fluorescein diphosphate. With the addition of a fixed concentration of fluoresceinated biotin and avidin, any free fluorescein generated by the phosphatase reaction gave additional fluorescence to the fixed signal, creating a reduced mP value. The concentration of FDP used in the assay was 2500 nM, and the concentration of biotinylated fluorescein was 1200 nM. When screening the LOPAC™ sample set, none of the 7 fluorescent compounds interfered with the assay, and 1 compound inhibited the assay. The lack of compound interference, as in the protease assay, was attributed to the minimal fluorescence contribution from the fluorescent compounds versus the high concentration of fluoresceinated biotin and free fluorescein generated in the stopped reaction. The compound identified as active was suramin hexasodium, which is a compound that has been shown to inhibit dephosphorylation of ATP 23 and is a known reversible and competitive inhibitor of protein tyrosine phosphatases. 24 
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Evaluation of red-shifted fluorophores
To further address ways to decrease fluorescence interference and light scattering from samples being tested, we looked at using the red-shifted Cy3B™ and Cy5™ fluorophores with LOPAC™ for kinase 1. Kinase 1 was chosen because this assay had the greatest level of fluorescent compound interference and used the lowest concentration of fluorophore, 1 nM. Both of these Cy™ dyes have the advantage that they are longer wavelength fluorophores and, therefore, should have minimal interference from fluorescent compounds, as seen using the standard fluorophore, fluorescein. These dyes should also reduce the affect that insoluble compounds have on the assay readout.
Initially, we ran the LOPAC™ samples in the kinase 1 buffer without fluorophore using the correct filters corresponding to the Cy3B™ and Cy5™ wavelength. The results for the TF values obtained with Cy3B™ and Cy5™ are shown in Figures 5 and 6 , respectively. These 2 figures show that none of the 80 mixtures interfered with the readout when compared to the respective control well, 1 nM Cy3B™ or 1 nM Cy5™, including the 8 identified as interfering when using the corresponding fluorescein filters. Comparison of Figures 5 and 6 with Figure 2 shows that fluorescent compounds play a big factor in affecting the TF signal when using fluorescein filters, and this interference was removed when using longer wavelength fluorophores and their associated filters.
Kinase assay 1 was run with LOPAC™ using the Cy3B™-PO 4peptide (5 nM) and Cy5™-PO 4 -peptide (1 nM) in place of the Fl-PO 4 -peptide (1 nM). The ∆mP for Cy3B™ was 125, and the Z′ was 0.82. For Cy5™, the ∆mP was 65 and the Z′ was 0.80. These results are slightly better than those found for fluorescein: ∆mP of 70 and Z′ of 0.70. A summary of the active compounds identified using the Cy™ dyes is shown in Table 6 , and comparisons can be made to the actives found using fluorescein in Table 3 . For the Cy3B™ study, the same 3 mixture wells identified as active using fluorescein were identified plus 1 additional mixture well. Upon deconvolution, H-9 dihydrochloride and sepiapterin were found to inhibit the kinase, whereas the dopamine analogs individually were not active. The additional active well deconvoluted into benextramine tetrahydrochloride. When Cy5™ was used, 2 of the 3 mixture wells identified as active using fluorescein or Cy3B™ were identified, and the additional active well when using only Cy3B™ was identified. The 1 mixture well that was not identified as active was the well that contained sepiapterin. The reason is that this hit is a false positive caused by light scattering from the compound's insolubility, which is reduced at a longer wavelength. Because Cy5™ is shifted further into the red region than Cy3B™, the light scattering from sepiapterin did not affect the assay's performance and therefore was not identified as a hit. Furthermore, there is no literature precedence indicating sepiapterin to be an inhibitor of kinases. The mixture wells that contained H-9 dihydrochloride, the 2 dopamine analogs, and benextramine tetrahydrochloride were strongly inhibitory. Upon deconvolution, H-9 dihydrochloride was marginally inhibitory, the 2 dopamine analogs were not active, and benextramine tetrahydrochloride remained the active compound identified, similar to the results found using Cy3B™.
CONCLUSIONS
Fluorescent compounds can cause interference in fluorescencebased FP assays. This interference is especially apparent in assays with lower concentrations of fluorophore. Our data illustrates that in the case of signal decrease assays when a fluorescent compound is present in the mixture, a real hit can be masked (false negative). In the case of signal increase assays, a false-positive mixture would be identified. There are, however, several ways to resolve or reduce the problem of fluorescent compound interference. Screening in singles would eliminate masking potential hits but would substantially increase the workload. Because the TF should be within a range, one can flag wells that deviate significantly from the controls. 8 Flagging, however, is only a means of identifying problematic wells, not a solution. Increasing the concentration of the fluorophore can reduce fluorescent compound interference; how- ever, assay sensitivity should be reevaluated for this change. The use of red-shifted fluorophores instead of the commonly used fluorescein may be the best way to minimize fluorescence interference as well as light scattering, as shown in this article.
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